TelyRx Holdings Inc. faces a steep decline as investors react to its latest financial performance.
In the latest trading session, TelyRx Holdings Inc. (TELY.TO) saw its stock price drop by 10.91%, closing at CA$2.45. This significant decline raises concerns about the company's financial health and investor sentiment.
Investor takeaway: TelyRx's recent performance highlights the volatility often seen in emerging healthcare companies, especially those still grappling with substantial losses despite increasing revenues.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$66.45M
52W high
$4.25
52W low
$2.00
1W change
+2.94%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 144.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+144.9% Upside
Current Price
C$2.45
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
83.1%
Annualized
90-Day Vol
92.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.05
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.31 | C$1.73 โ C$3.07 |
| 60 trading days | C$2.18 | C$1.45 โ C$3.26 |
| 90 trading days | C$2.05 | C$1.25 โ C$3.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
TelyRx Holdings Inc. sees a 10.91% drop in stock price.
The company's market cap now stands at CA$73,091,416, reflecting investor concerns over its profitability and future outlook.
Bull case
Despite the downturn, TelyRx reported a notable revenue increase in Q1 2026, suggesting potential for future growth if they can manage their losses effectively. The revenue rose to CA$19.4 million, up from CA$6.9 million in the same quarter last year. This shows that while the company is struggling with losses, it is also making strides in generating sales, which could set the stage for a turnaround.
Bear case
However, the company's net loss of CA$4.7 million and a profit margin of -18.17% indicate ongoing financial struggles. These factors may deter investors looking for stability, as many are concerned about whether TelyRx can sustain its business model in a competitive healthcare market. The stark contrast between rising revenues and persistent losses raises red flags for potential investors.
Advertisement
